Abstract:Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. The majority of patients can be cured under the treatment of R-CHOP, but one third of patients will relapse and have a worse prognosis. To exploring a biomarker which can predict clinical behavior may aid in the implementation of novel therapeutic strategies. Inhibitor of DNA-binding 3 (ID3) is a helix loop-helix transcription factor, which negatively regulates the cell proliferation. ID3 mutations occur in 34-68% of Bukitt's lymphoma (BL) and are assiociated with lymphomagenesis. A variety of nonsense and frameshift mutations in ID3 as well as missense mutations in the region encoding the HLH domain reduces or eliminates ID3 protein function in BL. ID3 mutation is rare in DLBCL. The prognostic value of ID3 protein level remains unclear in DLBCL. Therefore, we conducted a retrospective study to investigate the impact of ID3 expression in DLBCL patients. Methods: One hundred DLBCL patients treated at Fudan University Shanghai Cancer Center with available diagnostic biopsy material were identified. ID3 expression was determined and quantified by immunohistochemistry (IHC) with staining intensity and percentage of positive cells (IRS). The IRS cut off value for ID3 positive is equal or more than 6. Kaplan-Meier and life table method were used to calculate progression free survival (PFS) and overall survival (OS). Curves were compared with the long-rank test in both groups. Correlation between the ID3 expression and clinical variables were tested by Pearson Chi Square test and a two-sided P value of <0.05 was considered to be statistically significant. Result: Seventy-seven (77%) of patients was overexpressed ID3 and 23% patients was shown ID3 negative. Among these pateints, ID3 positive patients had a trend of better outcome without a significance. The PFS and OS were 65% and 68% in ID3 negative group; 80% and 85% in ID3 positive group, respectively. According to cell of origin, the ID3 deficiency were 24% (10/41) in GCB patients and 22% (13/59) in non-GCB patients (p=0.82). the ID3 overexpression was associated with a better OS compared with ID3 negative patients in non-germinal center B-cell lymphoma group (non-GCB) (85% vs 46%, p=0.047). Although the PFS of ID3 positive patients was better than negative group (77% vs 59%, p=0.256), there was no significance. In GCB patients, there was no differences between the ID3 positive group and negative groups in terms of PFS or OS. The basic characteristics were no difference between ID3 positive and negative groups. Conclusion: This is the first report demonstrating that ID3 overexpression is a positive predictor of clinical outcome in non-GCB lymphoma patients. ID3 is a potential novel target to treat lymphoma and further investigation of ID3 need to be done in the near future. (Research supported by National Natural Science Foundation of China (no.81670177, no.81001048) Figure Disclosures No relevant conflicts of interest to declare.

The Expression of Receptor Interaction Protein-3 in Lymphoma Patients Pathology Organization

Toll-like Receptor 3 and Tumor Immunity

Clinical significance and prognostic value of STAT 3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

[Study on Expression of Caspase-3 and Bcl-2 Proteins and Their Relations with Cell Apoptosis and Proliferation in Non-Hodgkin's Lymphoma].

Regulator of nonsense transcripts 3B is a prognostic biomarker and associated with immune cell infiltration in lung squamous cell and hepatocellular carcinoma

Expressions of Survivin and PLK1 in T-cell lymphoma and their clinical significances

Cellular Localization of a Novel Human Thrombospondin R-spondin 3 and Its Effects on Tumor Cells

High Expression of NDRG3 Associates with Positive Lymph Node Metastasis and Unfavourable Overall Survival in Laryngeal Squamous Cell Carcinoma.

Expression and prognostic value of ING3 in human primary hepatocellular carcinoma.

[Expression and Clinical Significance of CXCR3 in Mantle Cell Lymphoma].

The Expression of E2F1 and BIRC5 Protein in Malignant Lymphoma and Their Correlations

Expression and clinical significance of microRNA34a in non-Hodgkin′s lymphoma

Up-Regulation of RIP3 Alleviates Prostate Cancer Progression by Activation of RIP3/MLKL Signaling Pathway and Induction of Necroptosis

Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.

REEP3 is a potential diagnostic and prognostic biomarker correlated with immune infiltration in pancreatic cancer

Expression of FOXp3 and HLA-B mRNA in peripheral blood mononuclear cells of lymphoma patients

Expression of RECK in non-small cell lung cancer and its clinical significance

Study on the correlation between the expression of basic transcription factor 3 (BTF3) and the efficacy and prognosis of patients with malignant melanoma (MM).

Expression and Clinicopathological Implication of DcR3 in Lung Cancer Tissues: a Tissue Microarray Study with 365 Cases.

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma